We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Beactica Announces Drug Discovery Research Collaboration with GE Healthcare and Uppsala University

Read time: Less than a minute
Beactica has announced a new research collaboration agreement with GE Healthcare and Uppsala University (Sweden). The collaboration combines Beactica's approach to fragment-based drug discovery and GE Healthcare's Biacore™ technology with enzymology expertise from Uppsala University.

Under the terms of the agreement, the consortium will collaborate to develop the next generation of Biacore™ surface plasmon resonance instruments and applications for fragment-based drug discovery.

The project also aims to identify high-quality leads against a clincally important, undisclosed protein target from Beactica's discovery pipeline. Financial terms of the agreement were not disclosed.

"We look forward to deepening our relationship with GE Healthcare and Uppsala University," said Beactica's CEO, Dr Per Kallblad. "The Biacore technology is a core component of our kinetics-integrated lead discovery platform. Being an active part in the development of next - generation applications from GE Healthcare will enable us to stay at the forefront of our field."
Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.